10-Q Filing

MERCK & CO., INC. CIK: 310158 Q3 2017

Filing Information

Form Type	10-Q
Accession Number	`0000310158-17-000045`
Period End Date	20170930
Filing Date	20171107
Fiscal Year	2017
Fiscal Period	Q3
XBRL Instance	mrk-20170930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 80 Income Statement 60 Cash Flow Statement 60 Comprehensive Income 28

Balance Sheet 80 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$222.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$195.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$1.03B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$1.12B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.51B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.91B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.90B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$15.75B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$16.66B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.52B	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$7.83B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$3.29B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $222 in 2017 and $195 in 2016)	`AccountsReceivableNetCurrent`	$7.67B	USD	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, shares authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $222 in 2017 and $195 in 2016)	`AccountsReceivableNetCurrent`	$7.02B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $1,029 in 2017 and $1,117 in 2016 classified in Other assets - see Note 5)	`InventoryNet`	$5.26B	USD	Point-in-time
Inventories (excludes inventories of $1,029 in 2017 and $1,117 in 2016 classified in Other assets - see Note 5)	`InventoryNet`	$4.87B	USD	Point-in-time
Treasury stock, shares (shares)	`TreasuryStockShares`	850.70M	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$3.79B	USD	Point-in-time
Treasury stock, shares (shares)	`TreasuryStockShares`	828.37M	shares	Point-in-time
Other current assets	`DeferredIncomeTaxesAndOtherAssetsCurrent`	$4.39B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$27.92B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$30.61B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$11.42B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$12.21B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $16,661 in 2017 and $15,749 in 2016	`PropertyPlantAndEquipmentNet`	$12.03B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $16,661 in 2017 and $15,749 in 2016	`PropertyPlantAndEquipmentNet`	$12.19B	USD	Point-in-time
Goodwill	`Goodwill`	$18.34B	USD	Point-in-time
Goodwill	`Goodwill`	$18.16B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$15.14B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$17.30B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$5.88B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$5.85B	USD	Point-in-time
Total Assets	`Assets`	$91.68B	USD	Point-in-time
Total Assets	`Assets`	$95.38B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$568.00M	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$5.16B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$2.62B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$2.81B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$10.27B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$9.99B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$396.00M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.24B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.32B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.30B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$19.47B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.20B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$21.84B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$24.27B	USD	Point-in-time
Deferred Income Taxes	`DeferredTaxLiabilitiesNoncurrent`	$4.16B	USD	Point-in-time
Deferred Income Taxes	`DeferredTaxLiabilitiesNoncurrent`	$5.08B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.51B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$7.71B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2017 and 2016	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2017 and 2016	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.94B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.82B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$44.13B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$43.70B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.23B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-4.95B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$80.37B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$80.63B	USD	Point-in-time
Less treasury stock, at cost: 850,698,697 shares in 2017 and 828,372,200 shares in 2016	`TreasuryStockValue`	$42.12B	USD	Point-in-time
Less treasury stock, at cost: 850,698,697 shares in 2017 and 828,372,200 shares in 2016	`TreasuryStockValue`	$40.55B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$38.25B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$40.09B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$220.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$251.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$43.96B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.31B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$44.77B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.50B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$95.38B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$91.68B	USD	Point-in-time

Income Statement 60 line items

Line Item	Tag	Value	Unit	Period
Sales	`SalesRevenueGoodsNet`	$29.69B	USD	3 Qtrs
Sales	`SalesRevenueGoodsNet`	$10.32B	USD	1 Quarter
Sales	`SalesRevenueGoodsNet`	$29.69B	USD	3 Qtrs
Sales	`SalesRevenueGoodsNet`	$10.54B	USD	1 Quarter
Materials and production	`CostOfGoodsSold`	$3.41B	USD	1 Quarter
Materials and production	`CostOfGoodsSold`	$9.37B	USD	3 Qtrs
Materials and production	`CostOfGoodsSold`	$3.27B	USD	1 Quarter
Materials and production	`CostOfGoodsSold`	$10.56B	USD	3 Qtrs
Marketing and administrative	`SellingGeneralAndAdministrativeExpense`	$7.25B	USD	3 Qtrs
Marketing and administrative	`SellingGeneralAndAdministrativeExpense`	$2.39B	USD	1 Quarter
Marketing and administrative	`SellingGeneralAndAdministrativeExpense`	$2.40B	USD	1 Quarter
Marketing and administrative	`SellingGeneralAndAdministrativeExpense`	$7.17B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$4.38B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.66B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.47B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$7.93B	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$153.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$470.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$161.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$386.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-22.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-30.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-88.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$86.00M	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$7.65B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$23.68B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$25.05B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.12B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$200.00M	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$6.01B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$2.89B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.64B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.49B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$251.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.19B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$699.00M	USD	1 Quarter
Net (Loss) Income	`ProfitLoss`	$3.46B	USD	3 Qtrs
Net (Loss) Income	`ProfitLoss`	$-51.00M	USD	1 Quarter
Net (Loss) Income	`ProfitLoss`	$2.19B	USD	1 Quarter
Net (Loss) Income	`ProfitLoss`	$4.53B	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$13.00M	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$4.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$16.00M	USD	3 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.18B	USD	1 Quarter
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.44B	USD	3 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.51B	USD	3 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$-56.00M	USD	1 Quarter
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.79	USD	1 Quarter
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.26	USD	3 Qtrs
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$-0.02	USD	1 Quarter
Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.63	USD	3 Qtrs
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.25	USD	3 Qtrs
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.78	USD	1 Quarter
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.62	USD	3 Qtrs
(Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$-0.02	USD	1 Quarter
Dividends Declared per Common Share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$0.46	USD	1 Quarter
Dividends Declared per Common Share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.41	USD	3 Qtrs
Dividends Declared per Common Share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$0.47	USD	1 Quarter
Dividends Declared per Common Share (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.38	USD	3 Qtrs

Cash Flow Statement 60 line items

Line Item	Tag	Value	Unit	Period
Net income	`ProfitLoss`	$3.46B	USD	3 Qtrs
Net income	`ProfitLoss`	$-51.00M	USD	1 Quarter
Net income	`ProfitLoss`	$2.19B	USD	1 Quarter
Net income	`ProfitLoss`	$4.53B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$3.51B	USD	3 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$4.29B	USD	3 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$572.00M	USD	3 Qtrs
Intangible asset impairment charges	`ImpairmentOfIntangibleAssetsExcludingGoodwill`	$376.00M	USD	3 Qtrs
Charge for future payments related to AstraZeneca collaboration license options	`ChargeForLicenseOptionsRelatedToCollaboration`	-	USD	3 Qtrs
Charge for future payments related to AstraZeneca collaboration license options	`ChargeForLicenseOptionsRelatedToCollaboration`	$750.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-65.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-601.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$225.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$77.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$232.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$76.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$-200.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$31.00M	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$5.26B	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$3.00B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$6.74B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$2.43B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.17B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$1.06B	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$8.40B	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$10.08B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$11.30B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$12.53B	USD	3 Qtrs
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$347.00M	USD	3 Qtrs
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$778.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$22.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-121.00M	USD	3 Qtrs
Net Cash Provided by (Used in) Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-647.00M	USD	3 Qtrs
Net Cash Provided by (Used in) Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$2.74B	USD	3 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$1.96B	USD	3 Qtrs
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$909.00M	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$301.00M	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$2.39B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$2.42B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$2.31B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.85B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$3.88B	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$790.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$481.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-167.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-109.00M	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-7.07B	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-4.22B	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash and Cash Equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$438.00M	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash and Cash Equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$353.00M	USD	3 Qtrs
Net Increase (Decrease) in Cash and Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$1.39B	USD	3 Qtrs
Net Increase (Decrease) in Cash and Cash Equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-617.00M	USD	3 Qtrs
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$6.51B	USD	Point-in-time
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$7.91B	USD	Point-in-time
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$7.90B	USD	Point-in-time
Cash and Cash Equivalents at Beginning of Year	`CashAndCashEquivalentsAtCarryingValue`	$8.52B	USD	Point-in-time
Cash and Cash Equivalents at End of Period	`CashAndCashEquivalentsAtCarryingValue`	$6.51B	USD	Point-in-time
Cash and Cash Equivalents at End of Period	`CashAndCashEquivalentsAtCarryingValue`	$7.91B	USD	Point-in-time
Cash and Cash Equivalents at End of Period	`CashAndCashEquivalentsAtCarryingValue`	$7.90B	USD	Point-in-time
Cash and Cash Equivalents at End of Period	`CashAndCashEquivalentsAtCarryingValue`	$8.52B	USD	Point-in-time

Comprehensive Income 28 line items

Line Item	Tag	Value	Unit	Period
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.18B	USD	1 Quarter
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.44B	USD	3 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.51B	USD	3 Qtrs
Net (Loss) Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$-56.00M	USD	1 Quarter
Net unrealized loss on derivatives, net of reclassifications	`OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent`	$-441.00M	USD	3 Qtrs
Net unrealized loss on derivatives, net of reclassifications	`OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent`	$-367.00M	USD	3 Qtrs
Net unrealized loss on derivatives, net of reclassifications	`OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent`	$-74.00M	USD	1 Quarter
Net unrealized loss on derivatives, net of reclassifications	`OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent`	$-66.00M	USD	1 Quarter
Net unrealized gain (loss) on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$135.00M	USD	1 Quarter
Net unrealized gain (loss) on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$213.00M	USD	3 Qtrs
Net unrealized gain (loss) on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$96.00M	USD	3 Qtrs
Net unrealized gain (loss) on investments, net of reclassifications	`OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent`	$-30.00M	USD	1 Quarter
Benefit plan net gain (loss) and prior service credit (cost), net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-13.00M	USD	1 Quarter
Benefit plan net gain (loss) and prior service credit (cost), net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$-86.00M	USD	3 Qtrs
Benefit plan net gain (loss) and prior service credit (cost), net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$144.00M	USD	1 Quarter
Benefit plan net gain (loss) and prior service credit (cost), net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$280.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$67.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$82.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$447.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$423.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$281.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$149.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-166.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-104.00M	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.72B	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.02B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$93.00M	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.41B	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.